Prognostic value of survivin, X-linked inhibitor of apoptosis protein and second mitochondria-derived activator of caspases expression in advanced non-small-cell lung cancer patients

Respirology

Volumn 15, Issue 3, 2010, Pages 501-509

  Chen, Ping ^a   Li, Jian ^a   Ge, Li Ping ^a   Dai, Chun Hua ^a   Li, Xiao Qin ^a  

^a AFFILIATED HOSPITAL OF JIANGSU UNIVERSITY   (China)

Author keywords

Non small cell lung cancer; Prognosis; Second mitochondria derived activator of caspase; Survivin; X linked inhibitor of apoptosis

Indexed keywords

ANTINEOPLASTIC AGENT; MESSENGER RNA; SECOND MITOCHONDRIAL ACTIVATOR OF CASPASE; SURVIVIN; X LINKED INHIBITOR OF APOPTOSIS;

ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER SURVIVAL; FEMALE; GENE EXPRESSION; HUMAN; HUMAN TISSUE; LARGE CELL CARCINOMA; LUNG ADENOCARCINOMA; LUNG NON SMALL CELL CANCER; LUNG SQUAMOUS CELL CARCINOMA; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGNOSIS; PROGRESSION FREE SURVIVAL; TRANSBRONCHIAL BIOPSY;

ADULT; AGED; ANTINEOPLASTIC AGENTS; BIOPSY; BRONCHI; CARCINOMA, NON-SMALL-CELL LUNG; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; LUNG NEOPLASMS; MALE; MICROTUBULE-ASSOCIATED PROTEINS; MIDDLE AGED; MITOCHONDRIAL PROTEINS; NEOPLASM STAGING; PREDICTIVE VALUE OF TESTS; PROGNOSIS; REGRESSION ANALYSIS; RETROSPECTIVE STUDIES; RNA, MESSENGER; TREATMENT OUTCOME; X-LINKED INHIBITOR OF APOPTOSIS PROTEIN;

EID: 77950192436     PISSN: 13237799     EISSN: 14401843     Source Type: Journal    
DOI: 10.1111/j.1440-1843.2010.01710.x     Document Type: Article

References (34)

1. Non-Small Cell Lung Cancer Collaborative Group. Chemotherapy in non-small cell lung cancer, a meta-analysis using updated data on individual patients from 52 randomized clinical trials. Br. Med. J. 1995 311 : 899 909.
2. Schiller JH, Harington D, Balani CP et al. Comparison of four chemotherapy regimens for advanced non-small cell lung cancer. N. Engl. J. Med. 2002 346 : 92 8.
3. Kerr JF, Winterford CM, Harmon BV. Apoptosis: its significance in cancer and cancer therapy. Cancer 1994 73 : 2013 2226.
4. Igney FH, Krammer PH. Death and anti-death: tumor resistance to apoptosis. Nat. Rev. Cancer 2002 2 : 227 288.
5. Yang L, Mashima T, Sato S et al. Predominant suppression of apoptosome by inhibitor of apoptosis protein in non-small cell lung cancer H460 cells: therapeutic effect of a novel polyarginine-conjugated Smac peptide. Cancer Res. 2003 63 : 831 837.
6. Checinska A, Hoogeland BS, Rodriguez JA et al. Role of XIAP in inhibiting cisplatin-induced caspase activation in non-small cell lung cancer cells: a small molecule Smac mimic sensitizes for chemotherapy-induced apoptosis by enhancing caspase-3 activation. Exp. Cell Res. 2007 313 : 1215 1224.
7. Salvesen GS, Duckett CS. IAP proteins: blocking the rood to death's door. Nat. Rev. Mol. Cell. Biol. 2002 3 : 401 410.
8. Altieri DC. Survivin, versatile modulation of cell division and apoptosis in cancer. Oncogene 2003 22 : 8581 8589.
9. Huang Y, Park YC, Rich RL et al. Structural basis of caspase inhibition by XIAP: differential roles of the linker versus the BIR domain. Cell 2001 104 : 227 288.
10. Holcik M, Gibson H, Korneluk RG. XIAP: apoptotic brake and promising therapeutic target. Apoptosis 2001 6 : 253 261.
11. Verhagen AM, Vaux DL. Cell death regulation by the mammalian IAP antagonist DIABLO/Smac. Apoptosis 2002 7 : 163 166.
12. Fulda S, Wick W, Weller M et al. Smac agonists sensitize for Apo2 L/TRAIL - or anticancer drug-induced apoptosis and induce regression of malignant glioma in vivo. Nat. Med. 2002 8 : 808 815.
13. Ng CP, Bonavida B. X-Linked inhibitor of apoptosis (XIAP) block Apo-2 ligand/tumor necrosis factor - related apoptosis-inducing ligand-mediated apoptosis of prostate cancer cell in the presence of mitochondrial activation: sensitization by overexpression of second mitochondria-derived activator of caspase/direct IAP-binding protein with low PI (Smac/DIABLO). Mol. Cancer Ther. 2002 1 : 1051 1058.
14. Vischioni B, van der Valk P, Span SW et al. Nuclear localization of survivin is a positive prognostic factor for survival in advanced non-small-cell lung cancer. Ann. Oncol. 2004 15 : 1654 1660.
15. Shinohara ET, Gonzalez A, Massion PP et al. Nuclear survivin predicts recurrence and poor survival in patients with resected nonsmall cell lung carcinoma. Cancer 2005 103 : 1685 1692.
16. Lu B, Gonzalez A, Massion PP et al. Nuclear survivin as a biomarker for non-small-cell lung cancer. Br. J. Cancer 2004 91 : 537 540.
17. Monzo M, Rosell R, Felip E et al. A novel anti-apoptosis gene: reexpression of survivin messenger RNA as a prognosis marker in non-small-cell lung cancer. J. Clin. Oncol. 1999 17 : 2100 2104.
18. Falleni M, Pellegrini C, Marchetti A et al. Survivin gene expression in early-stage non-small cell lung cancer. J. Pathol. 2003 200 : 620 626.
19. Ferreira CG, van der Valk P, Span SW et al. Expression of x-linked inhibitor of apoptosis as a novel prognostic marker in radically resected non-small cell lung cancer patients. Clin. Cancer Res. 2001 7 : 2468 2470.
20. Ferreira CG, van der Valk P, Span SW et al. Assessment of IAP (inhibitor of apoptosis) proteins as predictors of response to chemotherapy in advanced non-small-cell lung cancer patients. Ann. Oncol. 2001 12 : 799 805.
21. Sekimura A, Konishi A, Mizuno K et al. Expression of Smac/DIABLD is a novel prognostic maker in lung cancer. Oncol. Rep. 2004 11 : 797 802.
22. Mountain CF. Revision in the international system for staging lung cancer. Chest 1997 111 : 1710 1717.
23. Lord RVN, Brabender J, Gandara D et al. Low ERCC1 expression correlates with prolonged survival after cisplatin plus gemcitabine chemotherapy in non-small cell lung cancer. Clin. Cancer Res. 2002 8 : 2286 2291.
24. Ceppi P, Volante M, Novello S et al. ERCC1 and RRM1 gene expressions but not EGFR are predictive of shorter survival in advanced non-small-cell lung cancer treated with cisplatin and gemcitabine. Ann. Oncol. 2006 17 : 1818 1825.
25. Fortugno P, Wall NR, Giodini A et al. Survivin exists in immunochemically distinct subcellular pools and is involved in spindle microtubule function. J. Cell Sci. 2002 115 : 757 585.
26. Zaffaroni N, Pennati M, Collella G et al. Expression of the antiapoptotic gene survivin correlates with taxol resistance in human ovarian cancer. Cell. Mol. Life Sci. 2002 59 : 1406 1412.
27. Pennati M, Collella G, Folini M et al. Ribozyme-mediated attenuation of survivin expression sensitizes human melanoma cells to cisplatin-induced apoptosis. J. Clin. Invest. 2002 109 : 285 286.
28. Fan J, Wang L, Jiang G-N et al. The role of survivin on overall survival of non-small cell lung cancer, a meta-analysis of published literatures. Lung Cancer 2008 61 : 91 6.
29. Asselin E, Mills GB, Tsang BK. XIAP regulates Akt and caspase-3-dependent cleavage during cisplatin-induced apoptosis in human ovarian epithelial cancer cells. Cancer Res. 2001 61 : 1862 1868.
30. Lopes RB, Gangeswaran R, McNeish IA et al. Expression of the IAP protein family is dysregulated in pancreatic cancer cells and is important for resistance to chemotherapy. Int. J. Cancer 2007 120 : 2344 2352.
31. Krajewska M, Kim H, Kim C et al. Analysis of apoptosis protein expression in early-stage colorectal cancer suggests opportunities for new prognostic biomarkers. Clin. Cancer Res. 2005 11 : 5451 5461.
32. Liu SS, Tsang BK, Cheung AN et al. Anti-apoptotic proteins, apoptotic and proliferative parameters and their prognostic significance in cervical carcinoma. Eur. J. Cancer 2001 37 : 1104 1110.
33. Ferreira CG, Span SW, Peters GJ et al. Chemotherapy triggers apoptosis in a caspase-8-dependent and mitochondria-controlled manner in the non-small-cell lung cancer cell ling NCI-H460. Cancer Res. 2000 60 : 7133 7141.
34. Mizutani Y, Nakaishi H, Yamamoto K et al. Downregulation of Smac/DIABLO expression in renal cell carcinoma and its prognostic significance. J. Clin. Oncol. 2005 23 : 448 454.